Steven Tong
@steventong.bsky.social
Infectious diseases, clinical trials, staphylococcus and streptococcus. Reader and runner. Go Hawks!
@seanong.bsky.social is giving his PhD oration today at 12.30pm AEDT. If you are free, you will learn heaps about clinical trials in infectious diseases. It's been an incredible PhD journey!
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
November 16, 2025 at 10:53 PM
@seanong.bsky.social is giving his PhD oration today at 12.30pm AEDT. If you are free, you will learn heaps about clinical trials in infectious diseases. It's been an incredible PhD journey!
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
Check this out! A Cultural Information Hub from the #SNAPTrial. Hopefully the collation of resources are useful for any research projects wanting to build cultural competence among research staff and teams.
@nhmrc.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @thekidsau.bsky.social
@nhmrc.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @thekidsau.bsky.social
We have launched the #SNAPTrial Cultural Information Hub.
Leadership in clinical trial training & cultural safety from our Australian Aboriginal Advisory Committee.
www.snaptrial.com.au/cultural-inf...
Inclusivity & equity in recruiting participants
@steventong.bsky.social
Leadership in clinical trial training & cultural safety from our Australian Aboriginal Advisory Committee.
www.snaptrial.com.au/cultural-inf...
Inclusivity & equity in recruiting participants
@steventong.bsky.social
November 16, 2025 at 2:23 AM
Check this out! A Cultural Information Hub from the #SNAPTrial. Hopefully the collation of resources are useful for any research projects wanting to build cultural competence among research staff and teams.
@nhmrc.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @thekidsau.bsky.social
@nhmrc.bsky.social @unimelb.bsky.social @thedohertyinst.bsky.social @thekidsau.bsky.social
@seanong.bsky.social takes to the next level analysis of the BALANCE trial (7 vs 14 days of antibiotics) and impact of protocol non-adherence (there was about 20% non-adherence to protocol durations).
Read his thread and read his paper!
@thelancetinfdis.bsky.social @thedohertyinst.bsky.social
Read his thread and read his paper!
@thelancetinfdis.bsky.social @thedohertyinst.bsky.social
Hot off the press at @thelancetinfdis.bsky.social: our paper diving into non-adherence in the BALANCE trial. We identify factors associated with protocol non-adherence, and evaluate the impact of potential bias on trial results.
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
authors.elsevier.com
November 12, 2025 at 1:30 AM
@seanong.bsky.social takes to the next level analysis of the BALANCE trial (7 vs 14 days of antibiotics) and impact of protocol non-adherence (there was about 20% non-adherence to protocol durations).
Read his thread and read his paper!
@thelancetinfdis.bsky.social @thedohertyinst.bsky.social
Read his thread and read his paper!
@thelancetinfdis.bsky.social @thedohertyinst.bsky.social
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
We are looking for candidates for a new fully-funded joint PhD position at the Universities of Toronto and Melbourne, working on RCTs in bloodstream infection (BALANCE+, SNAP, STRAP).
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
forms.gle
October 27, 2025 at 9:28 AM
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!
New podcast @steventong.bsky.social
Buzzsprout - www.buzzsprout.com/1740310/epis...
Apple - podcasts.apple.com/gb/podcast/i...
Spotify - open.spotify.com/episode/588l...
Buzzsprout - www.buzzsprout.com/1740310/epis...
Apple - podcasts.apple.com/gb/podcast/i...
Spotify - open.spotify.com/episode/588l...
In Conversation with Steven Tong and Joshua Davis on adaptive platform trials - The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing...
www.buzzsprout.com
October 23, 2025 at 11:38 AM
Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!
Reposted by Steven Tong
We’re kicking off #Antimicrobials2026 with Symposium 1: Staphylococcus aureus, featuring two outstanding speakers.
💊 Prof @steventong.bsky.social
SNAP Update
🧬 Prof Anton Y. Peleg
Daptomycin and MRSA
Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky
💊 Prof @steventong.bsky.social
SNAP Update
🧬 Prof Anton Y. Peleg
Daptomycin and MRSA
Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky
October 23, 2025 at 6:06 AM
We’re kicking off #Antimicrobials2026 with Symposium 1: Staphylococcus aureus, featuring two outstanding speakers.
💊 Prof @steventong.bsky.social
SNAP Update
🧬 Prof Anton Y. Peleg
Daptomycin and MRSA
Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky
💊 Prof @steventong.bsky.social
SNAP Update
🧬 Prof Anton Y. Peleg
Daptomycin and MRSA
Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky
Reposted by Steven Tong
🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
October 19, 2025 at 4:34 AM
🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...
International funding flows in infectious diseases clinical trials published in selected high-impact journals over a 10-year period
New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.
See thread for details.
@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky
New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.
See thread for details.
@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky
Our new paper in @cmijournal.bsky.social led by the brilliant Hadrien Moffroid, a junior colleague in Melbourne. We examined international funding flows in ID RCTs published in selected high-impact journals over a 10-year period.
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
September 29, 2025 at 10:48 PM
International funding flows in infectious diseases clinical trials published in selected high-impact journals over a 10-year period
New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.
See thread for details.
@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky
New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.
See thread for details.
@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky
Reposted by Steven Tong
Free access to our article on the inclusion of LMICs in platform trials of bloodstream infections. SNAP in Johannesburg. @steventong.bsky.social @gurujosh.bsky.social
authors.elsevier.com/a/1lVzy,RGPg...
authors.elsevier.com/a/1lVzy,RGPg...
authors.elsevier.com
July 29, 2025 at 6:18 AM
Free access to our article on the inclusion of LMICs in platform trials of bloodstream infections. SNAP in Johannesburg. @steventong.bsky.social @gurujosh.bsky.social
authors.elsevier.com/a/1lVzy,RGPg...
authors.elsevier.com/a/1lVzy,RGPg...
Reposted by Steven Tong
Glad to have the opportunity to collaborate with Spanish colleagues on this. We conducted a pooled Bayesian post-hoc analysis of the BACSARM and SAFO trials evaluating combination therapy with fosfomycin for SAB. The door may not be closed on adjunctive fosfomycin! Justifies need for more RCTs.
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post-hoc Analysis of Individual Participant Data from Two Randomized Trials
✅ Just Accepted
#IDSky
✅ Just Accepted
#IDSky
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post-hoc Analysis of Individual Participant Data from Two Randomized Trials
The role of adjunctive fosfomycin in Staphylococcus aureus bacteremia (SAB) remains uncertain.
doi.org
July 18, 2025 at 12:53 AM
Glad to have the opportunity to collaborate with Spanish colleagues on this. We conducted a pooled Bayesian post-hoc analysis of the BACSARM and SAFO trials evaluating combination therapy with fosfomycin for SAB. The door may not be closed on adjunctive fosfomycin! Justifies need for more RCTs.
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial has been nominated for a Patient healthcare communication award!
Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...
Find out more about SNAP 🔗 www.snaptrial.com.au
Give us a vote!!
@thedohertyinst.bsky.social
Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...
Find out more about SNAP 🔗 www.snaptrial.com.au
Give us a vote!!
@thedohertyinst.bsky.social
SNAP Trial – Staphylococcus aureus Network Adaptive Platform Trial
SNAP aims to improve treatment outcomes for patients with Staphylococcus aureus bloodstream infections. This website provides information for participants, members of the public, and healthcare profes...
www.snaptrial.com.au
July 8, 2025 at 3:37 AM
The Staphylococcus aureus Network Adaptive Platform (SNAP) trial has been nominated for a Patient healthcare communication award!
Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...
Find out more about SNAP 🔗 www.snaptrial.com.au
Give us a vote!!
@thedohertyinst.bsky.social
Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...
Find out more about SNAP 🔗 www.snaptrial.com.au
Give us a vote!!
@thedohertyinst.bsky.social
Reposted by Steven Tong
Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:
doi.org/10.1186/s128...
#idsky #MedSky #HepSky #LiverSky
doi.org/10.1186/s128...
#idsky #MedSky #HepSky #LiverSky
July 2, 2025 at 1:31 AM
Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:
doi.org/10.1186/s128...
#idsky #MedSky #HepSky #LiverSky
doi.org/10.1186/s128...
#idsky #MedSky #HepSky #LiverSky
Reposted by Steven Tong
Thankful for another opportunity to write this editorial with @steventong.bsky.social in @jama.com: jamanetwork.com/journals/jam...
We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...
We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...
Trials Within Trials—Optimizing the Delivery of RCTs
In the latest issue of JAMA, Johansen and colleagues1 report the results of a trial that investigated the impact of digital recruitment letter formats on recruitment to a larger clinical trial, the DA...
jamanetwork.com
June 26, 2025 at 3:03 AM
Thankful for another opportunity to write this editorial with @steventong.bsky.social in @jama.com: jamanetwork.com/journals/jam...
We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...
We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...
Reposted by Steven Tong
Tuberculosis (TB), an infectious disease caused by bacteria, was responsible for as many as one-quarter of all deaths in the US and Europe during parts of the 18th and 19th centuries.
However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.
However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.
June 19, 2025 at 11:01 AM
Tuberculosis (TB), an infectious disease caused by bacteria, was responsible for as many as one-quarter of all deaths in the US and Europe during parts of the 18th and 19th centuries.
However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.
However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.
Reposted by Steven Tong
Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...
We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.
@steventong.bsky.social @gurujosh.bsky.social
doi.org/10.1093/cid/...
We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.
@steventong.bsky.social @gurujosh.bsky.social
Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers
Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,
doi.org
June 16, 2025 at 1:55 AM
Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...
We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.
@steventong.bsky.social @gurujosh.bsky.social
doi.org/10.1093/cid/...
We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.
@steventong.bsky.social @gurujosh.bsky.social
Reposted by Steven Tong
Dr K Gibney flys the flag for 🦘 clin trials by 🎺
ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon)
STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish)
Only enrolling in Aus for now but looking for int. collab.
#LISSSD25 #idsky #clinicaltrials #strep
ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon)
STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish)
Only enrolling in Aus for now but looking for int. collab.
#LISSSD25 #idsky #clinicaltrials #strep
June 5, 2025 at 1:24 AM
Dr K Gibney flys the flag for 🦘 clin trials by 🎺
ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon)
STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish)
Only enrolling in Aus for now but looking for int. collab.
#LISSSD25 #idsky #clinicaltrials #strep
ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon)
STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish)
Only enrolling in Aus for now but looking for int. collab.
#LISSSD25 #idsky #clinicaltrials #strep
Reposted by Steven Tong
Kick off the new season with our latest issue. 😄
June 4, 2025 at 8:41 AM
Kick off the new season with our latest issue. 😄
Have joined a Push-Up challenge to raise awareness and funds for mental health. 3,214 push-ups in 23 days.
www.thepushupchallenge.com.au/fundraiser/s...
www.thepushupchallenge.com.au/fundraiser/s...
Donate to level-up mental health in Australia
Help raise funds for much-needed mental health services and initiatives by donating to my page. I’m completing The Push-Up Challenge to support this great cause and would love your help to reach my fu...
www.thepushupchallenge.com.au
June 3, 2025 at 12:28 PM
Have joined a Push-Up challenge to raise awareness and funds for mental health. 3,214 push-ups in 23 days.
www.thepushupchallenge.com.au/fundraiser/s...
www.thepushupchallenge.com.au/fundraiser/s...
Exciting to see this new adaptive platform trial!
For pregnant women and people who are at risk of preterm birth, and babies born preterm.
PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS)
@platipus.bsky.social @drbretty.bsky.social
First domains will be: PROMOAT and BabyCINO
For pregnant women and people who are at risk of preterm birth, and babies born preterm.
PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS)
@platipus.bsky.social @drbretty.bsky.social
First domains will be: PROMOAT and BabyCINO
We're pleased to share our first animation, that aims to grow potential participant awareness of PLATIPUS and how it works.
Special thanks to Stephanie Hebbard, Kelly Fredell, Tara Lofhelm, PLATIPUS Lived Experience Committee and others who helped create this.
www.platipustrial.org/participants...
Special thanks to Stephanie Hebbard, Kelly Fredell, Tara Lofhelm, PLATIPUS Lived Experience Committee and others who helped create this.
www.platipustrial.org/participants...
May 21, 2025 at 12:51 PM
Exciting to see this new adaptive platform trial!
For pregnant women and people who are at risk of preterm birth, and babies born preterm.
PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS)
@platipus.bsky.social @drbretty.bsky.social
First domains will be: PROMOAT and BabyCINO
For pregnant women and people who are at risk of preterm birth, and babies born preterm.
PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS)
@platipus.bsky.social @drbretty.bsky.social
First domains will be: PROMOAT and BabyCINO
Always a privilege to write with @seanong.bsky.social!
Honoured to be invited to write this commentary with @steventong.bsky.social, on an excellent target trial emulation study which showed that antibiotic use was not associated with improved outcomes in non-severe COVID-19.
jamanetwork.com/journals/jam...
#IDSky
jamanetwork.com/journals/jam...
#IDSky
Target Trial Emulation for Antibiotic Use in Acute COVID-19
This study by Pulia and colleagues1 reports results from a large population-based cohort using target trial emulation to examine the associations of antibiotic treatment with clinical outcomes in pati...
jamanetwork.com
May 20, 2025 at 12:19 AM
Always a privilege to write with @seanong.bsky.social!
Reposted by Steven Tong
Cefazolin vs Antistaphylococcal Penicillins for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review & Meta-Analysis
@connorprosty.bsky.social @seanong.bsky.social &c
Cefaz more effective, safer #idsky
www.clinicalmicrobiologyandinfection.com/article/S119... 🔓
@connorprosty.bsky.social @seanong.bsky.social &c
Cefaz more effective, safer #idsky
www.clinicalmicrobiologyandinfection.com/article/S119... 🔓
May 9, 2025 at 4:29 PM
Cefazolin vs Antistaphylococcal Penicillins for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review & Meta-Analysis
@connorprosty.bsky.social @seanong.bsky.social &c
Cefaz more effective, safer #idsky
www.clinicalmicrobiologyandinfection.com/article/S119... 🔓
@connorprosty.bsky.social @seanong.bsky.social &c
Cefaz more effective, safer #idsky
www.clinicalmicrobiologyandinfection.com/article/S119... 🔓
Reposted by Steven Tong
🆕💫 Systematic Review and Meta-Analysis
30 observational studies( SNAP & CloCeBa not included)
N: 3869
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky
www.clinicalmicrobiologyandinfection.com/article/S119...
30 observational studies( SNAP & CloCeBa not included)
N: 3869
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky
www.clinicalmicrobiologyandinfection.com/article/S119...
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis
There is debate on whether cefazolin or antistaphylococcal penicillins should be the
first-line treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.
Ongoing trials are invest...
www.clinicalmicrobiologyandinfection.com
May 9, 2025 at 9:55 AM
🆕💫 Systematic Review and Meta-Analysis
30 observational studies( SNAP & CloCeBa not included)
N: 3869
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky
www.clinicalmicrobiologyandinfection.com/article/S119...
30 observational studies( SNAP & CloCeBa not included)
N: 3869
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky
www.clinicalmicrobiologyandinfection.com/article/S119...
Reposted by Steven Tong
Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵:
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
Redirecting
doi.org
May 7, 2025 at 12:55 AM
Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵:
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
Reposted by Steven Tong
such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social
joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast
podcasts.apple.com/us/podcast/s...
joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast
podcasts.apple.com/us/podcast/s...
SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results
Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m
podcasts.apple.com
May 5, 2025 at 4:08 PM
such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social
joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast
podcasts.apple.com/us/podcast/s...
joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast
podcasts.apple.com/us/podcast/s...
Reposted by Steven Tong
🆕 Episode of #Breakpoints/Communicable:
Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025.
Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org
Listen to Communicable: communicable.transistor.fm
Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025.
Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org
Listen to Communicable: communicable.transistor.fm
May 4, 2025 at 10:01 PM
🆕 Episode of #Breakpoints/Communicable:
Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025.
Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org
Listen to Communicable: communicable.transistor.fm
Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025.
Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org
Listen to Communicable: communicable.transistor.fm